Clinical Trial Update: Open-Label Extension Study of Setmelanotide [Phase 3]

View source ↗

Summary

An open-label Phase 3 extension study of setmelanotide for obesity due to defects in the leptin–melanocortin pathway, currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity Associated with Defects in Leptin-melanocortin Pathway

Drugs mentioned

• IMCIVREE (setmelanotide)
• Setmelanotide (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Obesity Associated With Defects in Leptin-melanocortin Pathway | Phase 3 | Status: ENROLLING_BY_INVITATION